Dr. Robert Edward Reynolds, MD

Dr. Reynolds practices at Oklahoma Cancer and Blood Specialists in Oklahoma City, Oklahoma.

Dr. Reynolds' NPI, 1649275827, was assigned on June 15, 2005. Dr. Reynolds graduated from University of Oklahoma College of Medicine in 1996. Dr. Reynolds holds Oklahoma license 20272.

Dr. Reynolds' primary practice is Oklahoma Cancer and Blood Specialists, at 13301 N Meridian Ave, Oklahoma City, OK 73120 in Oklahoma County. The practice phone is (405) 752-0871.

Dr. Reynolds' primary practice is Oklahoma Cancer and Blood Specialists in Oklahoma City, Oklahoma. Dr. Reynolds is also affiliated with INTEGRIS Health Baptist Medical Center. The medical group on file is Oklahoma Cancer and Blood Specialists. Dmand AI also links Dr. Reynolds to 4 more hospitals, 3 group practices and clinics, 3 medical groups and 2 home health agencies, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reynolds practices, 10 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Reynolds' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Reynolds is licensed in Oklahoma.

CMS data shows 108,632 Medicare services from Dr. Reynolds across 30 procedure codes in 2024, for 506 Medicare patients. Medicare paid $1,470,904 for them. Every service was in an office.

CMS counts 506 Medicare patients who saw Dr. Reynolds in 2024. The largest group is 65 to 74, with 203 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reynolds' median patient age at 72, with 53% women.

In 2024, Dr. Reynolds wrote 2,224 Medicare Part D claims for 278 patients. 78% of them were for generic drugs. CMS names the drug for 1,862 of them, across 52 drugs with 11 or more claims each, at $3,338,455 in total drug cost. In 2023, CMS named 1,720 claims across 51 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Reynolds for performance year 2024, reported individually. Dr. Reynolds accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reynolds as offering telehealth.

Dmand AI links 2 papers to Dr. Reynolds in 2020. Dr. Reynolds' most frequent co-authors are Richard W. Hendershot, MD, David J. Sher, MD and Robert Dale Timmerman, MD.

CMS Open Payments shows 974 general payments to Dr. Reynolds from 94 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,929.

Dr. Reynolds graduated from University of Oklahoma College of Medicine in 1996.